IgA Nephropathy (IgAN)
Nephrology·MeSH: Glomerulonephritis, IGA
Prevalence
25.0 / 100K
Incidence
2.5 / 100K/yr
5 drugs in development·4 companies·3 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| FILSPARI® | Travere Therapeutics, Inc. (TVTX) |
Phase 3(1)
| Drug | Company |
|---|---|
| atrasentan | CHINOOK THERAPEUTICS, INC. (KDNY) |
Phase 2(2)
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| bion-1301 | CHINOOK THERAPEUTICS, INC. (KDNY) |
Compare drugs
Frequently asked questions
How many drugs are in development for IgA Nephropathy (IgAN)?
BioSniper tracks 5 drugs in development for IgA Nephropathy (IgAN) across 4 companies.
How many clinical trials target IgA Nephropathy (IgAN)?
There are 3 clinical trials targeting IgA Nephropathy (IgAN) tracked by BioSniper.
What is the prevalence of IgA Nephropathy (IgAN)?
The estimated prevalence of IgA Nephropathy (IgAN) is approximately 25.0 per 100,000 population.
Deep-dive into IgA Nephropathy (IgAN)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis